Cancer Trials Ireland

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: Private

Established: 1996-01-01

Employees: 11

Market Cap: -

Website: http://www.cancertrials.ie

Clinical Trials

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

Active, not recruiting

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Serous Ovarian Tumor
Endometrioid Carcinoma Ovary

Interventions: Genetic: Somatic and Germline BRCA1/2 Testing

First Posted Date: 2024-02-23

Last Posted Date: 2024-02-23

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 200

Registration Number: NCT06274541

Locations: 🇮🇪
Bon Secours, Cork, Munster, Ireland
🇮🇪
Cork University Hospital, Cork, Munster, Ireland
🇮🇪
University Hospital Limerick, Limerick, Munster, Ireland

and more 2 locations

Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)

Not Applicable

Recruiting

Conditions: Pancreatic Cancer

Interventions: Dietary Supplement: Control
Dietary Supplement: Intervention

First Posted Date: 2023-11-29

Last Posted Date: 2024-05-06

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 70

Registration Number: NCT06149546

Locations: 🇮🇪
St Vincent's University Hospital, Dublin, Leinster, Ireland

Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases

Phase 1

Recruiting

Conditions: Solid Tumor Spine Metastases

First Posted Date: 2023-10-12

Last Posted Date: 2024-12-09

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 126

Registration Number: NCT06078813

Locations: 🇮🇪
Bon Secours/UPMC, Cork, Ireland
🇮🇪
St Luke's Radiation Oncology Network (SLRON) at Beaumont Hospital, Dublin, Ireland
🇮🇪
Beacon Hospital, Dublin, Ireland

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

Phase 1

Recruiting

Conditions: Pancreatic Adenocarcinoma

Interventions: Radiation: Dose-Painted Intensity Modulated Radiotherapy

First Posted Date: 2023-09-06

Last Posted Date: 2024-02-23

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 49

Registration Number: NCT06024824

Locations: 🇮🇪
St Luke's Radiation Oncology Network (SLRON), Dublin, Ireland
🇮🇪
St Vincent's University Hospital, Dublin, Ireland

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Phase 2

Active, not recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: trastuzumab deruxtecan (T-DXd) (IV)

First Posted Date: 2023-02-02

Last Posted Date: 2024-08-05

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 11

Registration Number: NCT05710666

Locations: 🇮🇪
University Hospital Limerick, Limerick, Munster, Ireland
🇮🇪
Saint Vincent's University Hospital, Dublin, Leinster, Ireland
🇮🇪
Cork University Hospital, Cork, Munster, Ireland

and more 2 locations

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Trametinib
Drug: Hydroxychloroquine

First Posted Date: 2022-08-26

Last Posted Date: 2023-06-18

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 22

Registration Number: NCT05518110

Locations: 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪
St Vincent's University Hospital, Dublin, Ireland

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone (IV)

First Posted Date: 2021-11-17

Last Posted Date: 2023-06-01

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 43

Registration Number: NCT05123131

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland

and more 3 locations

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Cyclophosphamide
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2020-12-16

Last Posted Date: 2023-11-27

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 20

Registration Number: NCT04667663

Locations: 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
Galway University Hospital, Galway, Ireland
🇮🇪
Cork University Hospital, Cork, Ireland

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Paricalcitol
Drug: Gemcitabine (GEM) and Nab-paclitaxel

First Posted Date: 2020-11-05

Last Posted Date: 2024-03-06

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 15

Registration Number: NCT04617067

Locations: 🇮🇪
University Hospital Waterford, Waterford, Ireland
🇮🇪
Tallaght University Hospital, Dublin, Dublin 24, Ireland
🇮🇪
St. Vincent's University Hospital, Dublin, Dublin 4, Ireland

and more 3 locations

The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"

Terminated

Conditions: COVID-19
Cancer

First Posted Date: 2020-10-09

Last Posted Date: 2020-10-30

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 4

Registration Number: NCT04581070

Locations: 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪
University Hospital Limerick, Limerick, Ireland
🇮🇪
University Hospital Waterford, Waterford, Ireland

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy